Phreesia (PHR) Insider Gillian Munson Buys $185K of Stock

Gillian Munson Buys Phreesia Shares

Gillian Munson picked up 19,290 shares of Phreesia, Inc. (NYSE:PHR) on June 24, 2026. The stock was bought at a price of $9.59 per share, bringing the total value of the transaction to $184,991.10. This purchase joined a series of identical stock acquisitions made by other company insiders on the exact same day.

Coordinated Insider Activity at Phreesia

The late June buying wave involved several key figures at the healthcare technology firm. Jon Kessler, Lisa Egbuonu-Davis, Ramin Sayar, Smith Mark Douglas, and Lainie Goldstein each acquired an identical block of 19,290 shares at the same $9.59 price point, totaling $184,991.10 per person on June 24, 2026. These transactions brought a matching influx of insider commitments into the software provider during a single session.

Phreesia Stock Performance and Valuation

Phreesia shares have traded within a 52-week range spanning from a low of $7.77 to a high of $25.00. The company carries a forward P/E ratio of 6.24, alongside a trailing earnings per share of $0.18. Its 50-day moving average sits at $11.15, while the 200-day moving average rests at $11.81.

Analysts Set New Price Targets

Wall Street firms have kept a close eye on the healthcare software firm through various rating updates. On October 12, 2026, Barclays maintained its Equal-Weight rating while adjusting its price target to $11.00 from $10.00. Earlier in the autumn, Raymond James issued a downgrade to Market Perform on September 8, 2026. DA Davidson maintained a Buy rating on September 4, 2026, lowering its target to $13.00 from $14.00, while Baird kept a Neutral stance with an $11.00 target. Freedom Capital Markets reiterated a Buy rating at $14.00 on September 3, 2026, and RBC Capital kept an Outperform rating with a $19.00 target on the same day. Wells Fargo maintained an Equal-Weight rating on September 3, 2026, lifting its target to $10.00 from $9.00, and Canaccord Genuity maintained a Buy rating with a $16.00 target. Overall, the company holds a consensus buy rating with sixteen analyst opinions and a mean price target of $13.94.

About Phreesia, Inc.

Phreesia, Inc. operates an integrated software and payment platform designed for the healthcare sector. The company builds digital tools that help medical practices and health systems manage patient intake, appointments, clinical data capture, and billing workflows. Its platform aims to simplify administrative tasks for ambulatory practices, hospitals, and life sciences organizations across North America.

What to Watch at PHR

Investors will look toward the company's upcoming earnings report scheduled for December 7, 2026, to gauge revenue growth and financial progress. Future regulatory filings will also show whether insiders continue to adjust their holdings as market conditions evolve. These transactions are reported publicly through SEC forms and reflect historical disclosures rather than ongoing advice.